In The News This Week: Pfizer Hoping To Seek COVID Vaccine Approval For Children

FeaturedIn The News This Week: Pfizer Hoping To Seek COVID Vaccine Approval For Children

On ABC’s This Week on Sunday, Pfizer’s CEO Albert Bourla told George Stephanopoulos  that booster shots can be provided to older Americans, as well as shots for those who have yet to be vaccinated.

“I think it is also not the right thing to try to resolve it with an ‘or’ when you can resolve it with an ‘and,” he said. “It’s not shall we give boosters or give primary doses to other people. I think the answer is let’s give both boosters and doses to other people.”

CDC director Rochelle Walensky agrees with the agency’s advisory panel that medically vulnerable seniors should receive a booster shot of the vaccine, but the panel has rejected the recommendation that frontline workers receive a booster.

“We are looking forward to being able to vaccinate all these vulnerable people so that we can put an end to this pandemic,” Bourla said.

The debate over the need for a booster may seem unimportant, since some countries – poorer countries – have no vaccines at all. Former CDC director, Tom Frieden, criticized Pfizer and Moderna of not doing enough to supply vaccines to poorer nations.

“While focusing on selling expensive vaccines to rich countries, Moderna and Pfizer are doing next to nothing to close the global gap in vaccine supply. Shameful,” Frieden recently tweeted.

Recently, Pfizer released safety date regarding vaccines for children 05 to 11years of age. “I think we are going to submit this data very soon,” Bourla said. “A matter of days, not weeks.”

When the data has been reviewed and the FDA gives it’s approval, Bourla said Pfizer will begin inoculating children in that age group.

Sources: The Week, ABC News, NY Times.

In the News: Anti-Vax Students Sue Indiana University Over Vaccine Mandate

FeaturedIn the News: Anti-Vax Students Sue Indiana University Over Vaccine Mandate

A group of students at the University of Indiana recently filed a complaint over the school’s oppressive, unconstitutional vaccine mandate.

Justice Amy Coney-Barrett, who is the SC’s justice who oversees that regions emergency petitions, received a request from eight students to block the mandate and on Thursday, rejected the plea.

This past May, the university said that all students, faculty and staff must be vaccinated, unless they have legitimate reasons not to be vaccinated, such as a being a religious fanatic, or having a medical reason.

District judge Frank Easterbrook wrote in his ruling opinion:

Starting next semester, all students at Indiana University must be vaccinated against COVID-19 unless they are exempt for religious or medical reasons. Exempt students must wear masks and be tested for the disease twice a week. Eight students contend in this suit that these conditions of attendance violate due process clause of the Constitution’s fourteenth amendment. The district court denied plaintiffs’ request to a preliminary injunction, and they ask us to issue an injunction pending appeal.”

The application of the students who sued, reads:

“Students are facing IU’s imminent demand that they relinquish their Constitutional rights in order to start school this fall. And that it is coercing students to give up their bodily integrity, autonomy, and of medical treatment choice in exchange for the discretionary benefit of matriculating at IU.”

According to the right students the vaccines may be more dangerous than effects of the coronavirus.

“The risk of serious morbidity and mortality from COVID for those under thirty, ” their attorney, James Bopp, said in their defense, not citing any data to back up his claim, “is close to zero. The known and unknown risks associated with COVID vaccines, particularly in those under thirty, outweigh the risks to that population from the disease itself.”

As with any medication, there are risks involved in using those medications. Side effects are rare. I’ve had both shots of the Pfizer vaccine and have not experienced any side effects.

There is no reason for these students to refuse to be vaccinated. It’s all just a game to them. Everyone has to cater to the anti-vaxxers, the anti-maskers and their nonsense while they throw their public temper tantrums and insist they know what’s best, what’s true, and what the science really says. These people are largely the reason the pandemic is still a serious threat; we have millions of people who believe it’s government tyranny to have to follow health mandates designed to keep others and themselves safe.

Sources: Washington Post, The Week.

In The News: Pfizer Receives Authorization To Begin Administering It’s Vaccine To Adolescents

In The News: Pfizer Receives Authorization To Begin Administering It’s Vaccine To Adolescents

Pending CDC approval, the FDA has authorized the use of Pfizer’s BioNTech vaccine for distribution among twelve to fifteen year-olds. The vaccine had previously been approved for use in children sixteen and older.

The approval should come soon – possibly as soon as Wednesday – and after CDC go-ahead, immunization can begin as early as Thursday, as millions of children can now to return to school for the new year fully-immunized without fear of possibly transmitting the coronavirus.

“This is a watershed moment in our ability to fight back the COVID-19 pandemic,” said Dr. Bill Gruber, who is both a senior vice president of Pfizer, and a pediatrician.

“This is great news,” said Dr. Kristin Oliver, a pediatrician and vaccine expert at Mount Sinai Hospital in New York. “It’s as if we’ve been waiting forever to start protecting children in this age group.

Pfizer isn’t the only company reported attempting to get their vaccine used in lower age groups. Moderna has previously indicated that results from a pre-lim study of twelve to seventeen year-olds have demonstrated promising results without any serious side effects. And it is reported that Novavax has developed a vaccine and have begun their own clinical study on the effects of the vaccine on twelve to seventeen year-olds.

Children younger than twelve would be the next target for a vaccine approval. Moderna and Pfizer have been studying the effects of the vaccine in children from the ages between six months to eleven, and to determine the amount of dosing needed. Results are not expected until the coming weeks, probably some time this fall.

Sources: The Week, The NY Times.

In The News This Week: Pfizer Expected to Get Vaccine Authorization For Use In Adolescents

In The News This Week: Pfizer Expected to Get Vaccine Authorization For Use In Adolescents

Pfizer is expected get full authorization from the FDA to begin using the COVID vaccine on children between the ages 02 and 11. The FDA is likewise expected to begin distributing the Pfizer-BioNTech coronavirus vaccine in teens 12 15 as early as next week.

The pediatric safety study to determine the efficacy of the vaccine in children six months to eleven years, is currently on-going. According to Pfizer CEO, Albert Bourla, the results for children six months to two years, is not expected until the fourth quarter of this year, and the phase 02 safety data of Pfizer’s current study of the effect of the vaccine on pregnant women is expected sometime this summer.

Pfizer report previously that none of the Adolescents who participated in the trial developed infections, which is a sign of significant protection. The participants, however, produced anti-bodies and experienced some side effects seen in people ranging from 16 to 25 year olds.

Over 100 million adults have been fully-vaccinated. The authorization is an attempt to reach millions of more adults who have yet to receive their first dose.

Sources: CNN, NY Times.

In The News: Pfizer Requests FDA To Authorize COVID Vaccine For Children Ages 12 To 15

In The News: Pfizer Requests FDA To Authorize COVID Vaccine For Children Ages 12 To 15

Last week, Pfizer requested to extend the use of its COVID Vaccine to include children ages twelve to fifteen.

The request to the FDA is to amend the emergency use authorization, which they granted last year for teenagers sixteen and older.

Last week Pfizer-BioNTech reported that its phase three clinical trials were completely safe and effective in teenagers twelve to fifteen, but it’s findings had not been verified.

“The hope is to start vaccinating this age group before the start of the new school year,” said CEO Albert Bourla in a statement last week after the results were released.

“Vaccinating our teenagers is the next step in seeing our way through the pandemic,” said Dr. Buddy Creech, a pediatric infectious disease expert at Vanderbilt’s University Medical Center in Nashville, Tennessee.

“By extending the age groups that can receive the vaccine, we can continue our efforts to protect those that are most vulnerable: older adults as well as adults and teenagers with underlying medical conditions,” Creech continued, who was not involved in the research.

The FDA’s review will likely take several weeks, given the fact that the data looks good and is consistent with results observed in adults.

According to an NBC News database, one-third of Americans have received the first dose of the vaccine. But in order to vaccinate the whole population, vaccines will need to be authorized for children.

Sources: The Week, NBC News.